Nifurtimox is a nitrofuran-based antiparasitic drug primarily used in the treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, and more recently for African trypanosomiasis (sleeping sickness) in combination therapies. It works by generating reactive oxygen species (ROS) and nitro radicals that damage parasitic DNA, proteins, and membranes, leading to cell death.
Nifurtimox is administered orally, typically in multiple divided doses per day, and is approved for both pediatric and adult use.
Indications include:
∙ Chagas disease (especially acute and pediatric cases)
∙ Sleeping sickness (in combination with eflornithine or fexinidazole)
∙ Investigational use for other protozoal infections
Impurities in nifurtimox arise from its synthetic process, which involves nitration, furan ring formation, and hydrazone chemistry, and from degradation under heat, light, and oxidative stress. Given its use in neglected tropical diseases, impurity limits must comply with ICH Q3A/B, USP, EP, and WHO guidelines for essential medicines.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Nifurtimox is used to treat Chagas disease and, in some cases, African sleeping sickness, particularly in combination therapy. It is most effective in early-stage infections.
It generates toxic reactive oxygen species and nitro radicals that damage parasite DNA and cellular components, leading to parasitic death.
Yes. Nifurtimox is FDA-approved for pediatric use in treating Chagas disease, with weight-adjusted dosing.
No. It is sensitive to light, heat, and moisture, especially due to its nitrofuran moiety. It should be stored in airtight, light-protected containers at controlled room temperature.
